secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001104659-24-096047
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel licenses olutasidenib to Kissei for Japan, Korea, Taiwan; $10M upfront + up to $152.5M milestones
--------------------------------------------------------------------------------

- Rigel receives $10M upfront; eligible for up to $152.5M in development, regulatory, and commercial milestones.
- Mid-twenties to low-thirties percent tiered royalty on net sales; Kissei funds all development in territory.
- Forma Therapeutics (Novo Nordisk) owed $2.3M from the upfront payment under prior sublicense.
- Rigel retains global rights outside Japan, Korea, Taiwan; supplies bulk drug product under separate agreement.
- Kissei responsible for companion diagnostic costs in Japan; Rigel shares 50% up to $3M, creditable against milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924096047/0001104659-24-096047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924096047/tm2423224d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-096047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer